SCHEMBL2514287

SCHEMBL2514287

NC(=O)CC[C@H](N)C(=O)ON=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALOX15 P16050 1/20 0.54
▸ BLM P54132 1/20 0.54
▸ PMP22 Q01453 1/20 0.54
▸ KMT2A Q03164 1/20 0.54
▸ DPP4 P27487 1/20 0.40
▸ DPP8 Q6V1X1 1/20 0.40
▸ DPP9 Q86TI2 1/20 0.40
▸ GRM8 O00222 1/20 0.35
▸ GRM6 O15303 1/20 0.35
▸ GRIN2D O15399 1/20 0.35
▸ GRIN3B O60391 1/20 0.35
▸ GSR P00390 1/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ GRIK1 P39086 1/20 0.35
▸ GRM5 P41594 1/20 0.35
▸ GRIA1 P42261 1/20 0.35
▸ GRIA2 P42262 1/20 0.35
▸ GRIA3 P42263 1/20 0.35
▸ SLC1A3 P43003 1/20 0.35
▸ SLC1A2 P43004 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL711607 0.80 ALOX15 (0.60) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL28313344 0.80 ALOX15 (0.60) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL22440732 0.79 SLC1A2 (0.38) ALOX15DPP4DPP8DPP9GRIK1
SCHEMBL29588125 0.79 ANPEP (0.36) ALOX15BLMPMP22KMT2A
SCHEMBL167845 0.78 ALOX15 (0.58) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL1577692 0.78 ALOX15 (0.58) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL2516159 0.78 GSR (0.45) KMT2ADPP4DPP8DPP9GSR
SCHEMBL10192702 0.77 ALOX15 (0.56) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL9089896 0.77 ALOX15 (0.56) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL321431 0.77 ALOX15 (0.56) ALOX15BLMPMP22KMT2ADPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260115150-A1 FORMULATIONS COMPRISING INOSITOL, SILICATES, AND OPTIONALLY AMINO ACIDS WITH IMPROVED SOLUBILITY AND METHODS OF MAKING THE SAME NUTRITION21 LLC (US) 2026-04-30 — — US disclosed
US-12612370-B2 Amino acid compositions THERMOLIFE INTERNATIONAL, LLC (US) 2026-04-28 — — US disclosed
US-12577209-B2 Amino acid compositions THERMOLIFE INTERNATIONAL, LLC (US) 2026-03-17 — — US disclosed
US-12577210-B2 Amino acid compositions THERMOLIFE INTERNATIONAL, LLC (US) 2026-03-17 — — US disclosed
US-12540119-B2 Amino acid compositions THERMOLIFE INTERNATIONAL, LLC (US) 2026-02-03 — — US disclosed
US-12522568-B2 Amino acid compositions THERMOLIFE INTERNATIONAL, LLC (US) 2026-01-13 — — US disclosed
US-12473261-B2 Amino acid compositions THERMOLIFE INTERNATIONAL, LLC (US) 2025-11-18 — — US disclosed
US-12448357-B1 Amino acid compositions THERMOLIFE INTERNATIONAL, LLC (US) 2025-10-21 — — US disclosed
US-20250171406-A1 AMINO ACID COMPOSITIONS THERMOLIFE INTERNATIONAL, LLC 2025-05-29 — — US disclosed
US-20250162996-A1 AMINO ACID COMPOSITIONS THERMOLIFE INTERNATIONAL, LLC 2025-05-22 — — US disclosed
US-8344014-B2 — — 2013-01-01 — — US disclosed
US-20120220642-A1 Amino Acid Compounds THERMOLIFE INTERNATIONAL, LLC (US) 2012-08-30 — — US disclosed
US-20120220643-A1 Amino Acid Compounds THERMOLIFE INTERNATIONAL, LLC (US) 2012-08-30 — — US disclosed
US-8183288-B2 Amino acid compounds THERMOLIFE INTERNATIONAL, LLC (US) 2012-05-22 — — US disclosed
US-8178572-B2 Amino acid compounds THERMOLIFE INTERNATIONAL, LLC (US) 2012-05-15 — — US disclosed
US-20110313043-A1 Amino Acid Compositions THERMOLIFE INTERNATIONAL, LLC (US) 2011-12-22 — — US disclosed
US-8034836-B2 Amino acid compounds THERMOLIFE INTERNATIONAL, LLC (US) 2011-10-11 — — US disclosed
US-7777074-B2 Amino acid compounds THERMOLIFE INTERNATIONAL, LLC (US) 2010-08-17 — — US disclosed
US-20090105328-A1 Amino Acid Compounds THERMOLIFE INTERNATIONAL, LLC 2009-04-23 — — US disclosed
US-20090076110-A1 Amino Acid Compounds THERMOLIFE INTERNATIONAL, LLC 2009-03-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12473261-B2 Amino acid compositions ASNS, GLUL, ARGLU1 ALOX15 2572/4885BLM 4752/4885PMP22 4443/4885
US-20120220643-A1 Amino Acid Compounds AADAT, OAT, SLC1A5 ALOX15 2124/4885BLM 4693/4885PMP22 2043/4885
US-20250162996-A1 AMINO ACID COMPOSITIONS ASNS, SLC1A5, BCAT2 ALOX15 3313/4885BLM 4837/4885PMP22 4322/4885
US-12612370-B2 Amino acid compositions TNNT2, NPR1, NOS2 ALOX15 2601/4885BLM 4815/4885PMP22 1487/4885
US-12448357-B1 Amino acid compositions SLC6A15, SLC1A5, SLC6A19 ALOX15 2510/4885BLM 4587/4885PMP22 2518/4885
US-12540119-B2 Amino acid compositions NOS2, NOS1, NOS3 ALOX15 4000/4885BLM 4810/4885PMP22 4154/4885
US-20090076110-A1 Amino Acid Compounds OAT, ARGLU1, ASNS ALOX15 3711/4885BLM 3808/4885PMP22 2810/4885
US-12577209-B2 Amino acid compositions ARG1, NOS1, NOS2 ALOX15 3027/4885BLM 4747/4885PMP22 4392/4885
US-20090105328-A1 Amino Acid Compounds DNPEP, AADAT, ASNS ALOX15 2667/4885BLM 4840/4885PMP22 2965/4885
US-20250171406-A1 AMINO ACID COMPOSITIONS ASNS, GLUL, ARGLU1 ALOX15 2551/4885BLM 4760/4885PMP22 4469/4885
US-12577210-B2 Amino acid compositions NPR1, SLC1A5, SLC6A15 ALOX15 3144/4885BLM 4863/4885PMP22 4329/4885
US-20110313043-A1 Amino Acid Compositions ARGLU1, AADAT, MUSK ALOX15 3132/4885BLM 3648/4885PMP22 2870/4885
US-20260115150-A1 FORMULATIONS COMPRISING INOSITOL, SILICATES, AND OPTIONALLY AMINO ACIDS WITH IMPROVED SOLUBILITY AND METHODS OF MAKING THE SAME CUTA, NOS1, NOS2 ALOX15 3512/4885BLM 3655/4885PMP22 2782/4885
US-20120220642-A1 Amino Acid Compounds AADAT, SLC10A2, SLC6A12 ALOX15 1699/4885BLM 4262/4885PMP22 2490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback